Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

CT-P39, an omalizumab biosimilar, shows comparable efficacy and safety to the original in treating chronic spontaneous urticaria, enhancing patient access.

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

The Top 5 Biosimilars Articles for the Week of June 16

June 20, 2025

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

June 19, 2025

BioRationality: Commemorating the 15th Anniversary of the BPCIA

April 8th 2025

By Sarfaraz K. Niazi, PhD

Article

Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.

Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers

April 7th 2025

By Skylar Jeremias

Article

Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.

Early Success of Adalimumab Biosimilars Featured at AMCP 2025

April 5th 2025

By Skylar Jeremias

Article

High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).

The Top 5 Biosimilar Articles for the Week of March 31

April 4th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 31, 2025.

Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD

April 3rd 2025

By Cameron Santoro

Article

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.

Bevacizumab Biosimilars Reduce Costs While Maintaining Survival Outcomes in mCRC

April 2nd 2025

By Deana Ferreri, PhD

Article

Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness.

Biosimilars Gastroenterology Roundup: March 2025

April 1st 2025

By Skylar Jeremias

Article

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.

Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year

March 31st 2025

By Skylar Jeremias

Article

Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming profitability of biosimilars despite financial hurdles.

PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing

March 30th 2025

By Cameron Santoro

Article

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.

The Top 5 Biosimilar Articles for the Week of March 24

March 28th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 24, 2025.